Drug industry concerned about California Law allowing State to seek drug discounts

NewsGuard 100/100 Score

A new California law set to take effect in January 2007 "provides a glimpse of the type of government price controls the drug industry fears," the Boston Globe reports.

The measure is designed to secure price discounts of up to 60% from drug manufacturers for five million California residents, including those with low-incomes and seniors enrolled in the Medicare prescription drug benefit.

Although state officials say the measure is voluntary, the law also includes language that permits California in 2010 to remove from its Medicaid formulary treatments sold by companies that do not comply with the law.

According to the Globe, the "law is intended to help California's low-income and underinsured residents by leveraging their collective purchasing power."

It aims to lower the cash price of prescription brand-name drugs by 40% and generic drugs by 60%, according to Nicole Kasabian Evans, a spokesperson for the California Health and Human Services Agency.

Gov. Arnold Schwarzenegger (R) signed the measures in September despite objections from the pharmaceutical industry.

Jim Greenwood, chief executive of the Biotechnology Industry Organization, said, "At the end of the day, you have to have very healthy companies who have the resources to do the research and development of these drugs.

You're not going to get it on the cheap.

And you're not going to get it under a system of European-like price controls that have stifled innovation."

The Pharmaceutical Research and Manufacturers of America has called the measure "problematic" but has not filed to stop its implementation.

Jan Faiks, vice president of government affairs and law for PhRMA, said, "We support discounted drugs for Californians."

However, Faiks noted that the measure does not require pharmacists and other drug distributors to negotiate drug prices, adding, "Frankly I don't know where they are going to get those discounts."

A coalition of consumers and patient groups are now working to support the legislation, according to Earl Lui, a senior attorney for Consumers Union (Henderson, Boston Globe, 11/11).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising antibiotic resistance prompts shift to ecological research strategies in infection control